MESO250117P20000
- 3.30
- +0.60+22.22%
Mesoblast Newsroom
Mesoblast Says JPMorgan Chase Reduces Shareholding
Mesoblast Requests Trading Halt
Mesoblast Prepares to Launch FDA-approved Therapy for Pediatric Steroid-Refractory AGVHD | ASX:MSB
Mesoblast To Issue 10.2 Million Shares to Osiris Therapeutics Following US FDA Approval of Cell Treatment; Shares Fall 6%
Mesoblast Limited Announces Proposed Securities Issue
State Street Corporation Ceases Substantial Holding in Mesoblast
Trending Stocks Today | Treasure Global Surges 74.03% Post-Market
Mesoblast Stock Rockets to New 52-Week High
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
Express News | Mesoblast Shareholder Offers 2M Ordinary Shares Represented By 200K ADSs On Nasdaq Under Symbol "MESO" And Australian Exchange As "MSB"; Company To Receive $9.06 Per ADS Upon Warrant Exercise, No Proceeds From ADS Sales
Mesoblast Sees Major Change in Substantial Holding
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
ASX: Riding the Scariest Rollercoaster on the Sharemarket
This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
Jefferies Downgrades Mesoblast to Hold
Jefferies Downgrades Mesoblast to Hold From Buy; Price Target Is AU$2.30
Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $30
Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $15
Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $30